Quinolone resistance among Escherichia coli strains from community‐acquired urinary tract infections in Greece
Susceptibility data for 10 049 Escherichia coli isolates derived from community‐acquired urinary tract infections in Greece during the period January 2000 to June 2002 indicated 8.1% resistance to nalidixic acid and 36% resistance to ciprofloxacin. In a sample of 170 E. coli isolates, mutations in g...
Gespeichert in:
| Veröffentlicht in: | Clinical microbiology and infection 2004-01, Vol.10 (1), p.75-78 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 78 |
|---|---|
| container_issue | 1 |
| container_start_page | 75 |
| container_title | Clinical microbiology and infection |
| container_volume | 10 |
| creator | Chaniotaki, S. Giakouppi, P. Tzouvelekis, L. S. Panagiotakos, D. Kozanitou, M. Petrikkos, G. Avlami, A. Vatopoulos, A. C. |
| description | Susceptibility data for 10 049 Escherichia coli isolates derived from community‐acquired urinary tract infections in Greece during the period January 2000 to June 2002 indicated 8.1% resistance to nalidixic acid and 36% resistance to ciprofloxacin. In a sample of 170 E. coli isolates, mutations in gyrA (25 isolates) and parC (15 isolates) were consistent with the levels of resistance to quinolones. Previous exposure to quinolones and underlying chronic disease were independent risk factors for infection by quinolone‐resistant E. coli strains. |
| doi_str_mv | 10.1111/j.1469-0691.2004.00807.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80082772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19263852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4757-af3578ecaa9f509ac6e304ee726443045cad75a6eb8f5ed8f69e83a0456d9bb03</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhSNERUvhFZA3sEuw43-JDRqVFmlQVQkkdpbHuaYeJc7UTkRnxyPwjDxJHWZEl8UbX_l-59o-p6oQwQ0p6_22IUzoGgtNmhZj1mCssGzun1Vn_xrPS020qiWj30-rlzlvMcYtpexFdUqYxAJrclbtbuYQx36MgBLkkCcbHSA7jPEHusjuFlJwt8EiN_YB5SnZEDPyaRzKyTDMMUz7P79-W3c3hwQdmlOINu1RAd2EQvTgpjAWSYjoMgE4eFWdeNtneH3cz6tvny6-rq7q9fXl59XHde2Y5LK2nnKpwFmrPcfaOgEUMwDZCsZKxZ3tJLcCNspz6JQXGhS1pSE6vdlgel69O8zdpfFuhjyZIWQHfW8jjHM2qljWStk-CRLdCqr4AqoD6NKYcwJvdikM5beGYLPEYrZmcd8s7pslFvM3FnNfpG-Od8ybAbpH4TGHArw9AjY72_tUYgj5keOcMMxZ4T4cuJ-hh_1_P8Cs1l9KQR8Ag-SrwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19263852</pqid></control><display><type>article</type><title>Quinolone resistance among Escherichia coli strains from community‐acquired urinary tract infections in Greece</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Chaniotaki, S. ; Giakouppi, P. ; Tzouvelekis, L. S. ; Panagiotakos, D. ; Kozanitou, M. ; Petrikkos, G. ; Avlami, A. ; Vatopoulos, A. C.</creator><creatorcontrib>Chaniotaki, S. ; Giakouppi, P. ; Tzouvelekis, L. S. ; Panagiotakos, D. ; Kozanitou, M. ; Petrikkos, G. ; Avlami, A. ; Vatopoulos, A. C. ; WHONET Study Group</creatorcontrib><description>Susceptibility data for 10 049 Escherichia coli isolates derived from community‐acquired urinary tract infections in Greece during the period January 2000 to June 2002 indicated 8.1% resistance to nalidixic acid and 36% resistance to ciprofloxacin. In a sample of 170 E. coli isolates, mutations in gyrA (25 isolates) and parC (15 isolates) were consistent with the levels of resistance to quinolones. Previous exposure to quinolones and underlying chronic disease were independent risk factors for infection by quinolone‐resistant E. coli strains.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1111/j.1469-0691.2004.00807.x</identifier><identifier>PMID: 14706091</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Anti-Infective Agents - pharmacology ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Ciprofloxacin - pharmacology ; Community-Acquired Infections - epidemiology ; Community-Acquired Infections - microbiology ; Community‐acquired ; DNA Gyrase - genetics ; DNA Topoisomerase IV - genetics ; Drug Resistance, Bacterial ; Escherichia coli ; Escherichia coli - drug effects ; Escherichia coli - genetics ; Escherichia coli Infections - epidemiology ; Escherichia coli Infections - microbiology ; Greece ; Humans ; Infectious diseases ; Medical sciences ; Microbial Sensitivity Tests ; Nalidixic Acid - pharmacology ; Pharmacology. Drug treatments ; quinolones ; resistance ; urinary tract infection ; Urinary Tract Infections - epidemiology ; Urinary Tract Infections - microbiology</subject><ispartof>Clinical microbiology and infection, 2004-01, Vol.10 (1), p.75-78</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4757-af3578ecaa9f509ac6e304ee726443045cad75a6eb8f5ed8f69e83a0456d9bb03</citedby><cites>FETCH-LOGICAL-c4757-af3578ecaa9f509ac6e304ee726443045cad75a6eb8f5ed8f69e83a0456d9bb03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1469-0691.2004.00807.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1469-0691.2004.00807.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,4010,27900,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15514054$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14706091$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chaniotaki, S.</creatorcontrib><creatorcontrib>Giakouppi, P.</creatorcontrib><creatorcontrib>Tzouvelekis, L. S.</creatorcontrib><creatorcontrib>Panagiotakos, D.</creatorcontrib><creatorcontrib>Kozanitou, M.</creatorcontrib><creatorcontrib>Petrikkos, G.</creatorcontrib><creatorcontrib>Avlami, A.</creatorcontrib><creatorcontrib>Vatopoulos, A. C.</creatorcontrib><creatorcontrib>WHONET Study Group</creatorcontrib><title>Quinolone resistance among Escherichia coli strains from community‐acquired urinary tract infections in Greece</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>Susceptibility data for 10 049 Escherichia coli isolates derived from community‐acquired urinary tract infections in Greece during the period January 2000 to June 2002 indicated 8.1% resistance to nalidixic acid and 36% resistance to ciprofloxacin. In a sample of 170 E. coli isolates, mutations in gyrA (25 isolates) and parC (15 isolates) were consistent with the levels of resistance to quinolones. Previous exposure to quinolones and underlying chronic disease were independent risk factors for infection by quinolone‐resistant E. coli strains.</description><subject>Anti-Infective Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Ciprofloxacin - pharmacology</subject><subject>Community-Acquired Infections - epidemiology</subject><subject>Community-Acquired Infections - microbiology</subject><subject>Community‐acquired</subject><subject>DNA Gyrase - genetics</subject><subject>DNA Topoisomerase IV - genetics</subject><subject>Drug Resistance, Bacterial</subject><subject>Escherichia coli</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - genetics</subject><subject>Escherichia coli Infections - epidemiology</subject><subject>Escherichia coli Infections - microbiology</subject><subject>Greece</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Nalidixic Acid - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>quinolones</subject><subject>resistance</subject><subject>urinary tract infection</subject><subject>Urinary Tract Infections - epidemiology</subject><subject>Urinary Tract Infections - microbiology</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUhSNERUvhFZA3sEuw43-JDRqVFmlQVQkkdpbHuaYeJc7UTkRnxyPwjDxJHWZEl8UbX_l-59o-p6oQwQ0p6_22IUzoGgtNmhZj1mCssGzun1Vn_xrPS020qiWj30-rlzlvMcYtpexFdUqYxAJrclbtbuYQx36MgBLkkCcbHSA7jPEHusjuFlJwt8EiN_YB5SnZEDPyaRzKyTDMMUz7P79-W3c3hwQdmlOINu1RAd2EQvTgpjAWSYjoMgE4eFWdeNtneH3cz6tvny6-rq7q9fXl59XHde2Y5LK2nnKpwFmrPcfaOgEUMwDZCsZKxZ3tJLcCNspz6JQXGhS1pSE6vdlgel69O8zdpfFuhjyZIWQHfW8jjHM2qljWStk-CRLdCqr4AqoD6NKYcwJvdikM5beGYLPEYrZmcd8s7pslFvM3FnNfpG-Od8ybAbpH4TGHArw9AjY72_tUYgj5keOcMMxZ4T4cuJ-hh_1_P8Cs1l9KQR8Ag-SrwQ</recordid><startdate>200401</startdate><enddate>200401</enddate><creator>Chaniotaki, S.</creator><creator>Giakouppi, P.</creator><creator>Tzouvelekis, L. S.</creator><creator>Panagiotakos, D.</creator><creator>Kozanitou, M.</creator><creator>Petrikkos, G.</creator><creator>Avlami, A.</creator><creator>Vatopoulos, A. C.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200401</creationdate><title>Quinolone resistance among Escherichia coli strains from community‐acquired urinary tract infections in Greece</title><author>Chaniotaki, S. ; Giakouppi, P. ; Tzouvelekis, L. S. ; Panagiotakos, D. ; Kozanitou, M. ; Petrikkos, G. ; Avlami, A. ; Vatopoulos, A. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4757-af3578ecaa9f509ac6e304ee726443045cad75a6eb8f5ed8f69e83a0456d9bb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anti-Infective Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Ciprofloxacin - pharmacology</topic><topic>Community-Acquired Infections - epidemiology</topic><topic>Community-Acquired Infections - microbiology</topic><topic>Community‐acquired</topic><topic>DNA Gyrase - genetics</topic><topic>DNA Topoisomerase IV - genetics</topic><topic>Drug Resistance, Bacterial</topic><topic>Escherichia coli</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - genetics</topic><topic>Escherichia coli Infections - epidemiology</topic><topic>Escherichia coli Infections - microbiology</topic><topic>Greece</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Nalidixic Acid - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>quinolones</topic><topic>resistance</topic><topic>urinary tract infection</topic><topic>Urinary Tract Infections - epidemiology</topic><topic>Urinary Tract Infections - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chaniotaki, S.</creatorcontrib><creatorcontrib>Giakouppi, P.</creatorcontrib><creatorcontrib>Tzouvelekis, L. S.</creatorcontrib><creatorcontrib>Panagiotakos, D.</creatorcontrib><creatorcontrib>Kozanitou, M.</creatorcontrib><creatorcontrib>Petrikkos, G.</creatorcontrib><creatorcontrib>Avlami, A.</creatorcontrib><creatorcontrib>Vatopoulos, A. C.</creatorcontrib><creatorcontrib>WHONET Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chaniotaki, S.</au><au>Giakouppi, P.</au><au>Tzouvelekis, L. S.</au><au>Panagiotakos, D.</au><au>Kozanitou, M.</au><au>Petrikkos, G.</au><au>Avlami, A.</au><au>Vatopoulos, A. C.</au><aucorp>WHONET Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quinolone resistance among Escherichia coli strains from community‐acquired urinary tract infections in Greece</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2004-01</date><risdate>2004</risdate><volume>10</volume><issue>1</issue><spage>75</spage><epage>78</epage><pages>75-78</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>Susceptibility data for 10 049 Escherichia coli isolates derived from community‐acquired urinary tract infections in Greece during the period January 2000 to June 2002 indicated 8.1% resistance to nalidixic acid and 36% resistance to ciprofloxacin. In a sample of 170 E. coli isolates, mutations in gyrA (25 isolates) and parC (15 isolates) were consistent with the levels of resistance to quinolones. Previous exposure to quinolones and underlying chronic disease were independent risk factors for infection by quinolone‐resistant E. coli strains.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>14706091</pmid><doi>10.1111/j.1469-0691.2004.00807.x</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1198-743X |
| ispartof | Clinical microbiology and infection, 2004-01, Vol.10 (1), p.75-78 |
| issn | 1198-743X 1469-0691 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80082772 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Anti-Infective Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Ciprofloxacin - pharmacology Community-Acquired Infections - epidemiology Community-Acquired Infections - microbiology Community‐acquired DNA Gyrase - genetics DNA Topoisomerase IV - genetics Drug Resistance, Bacterial Escherichia coli Escherichia coli - drug effects Escherichia coli - genetics Escherichia coli Infections - epidemiology Escherichia coli Infections - microbiology Greece Humans Infectious diseases Medical sciences Microbial Sensitivity Tests Nalidixic Acid - pharmacology Pharmacology. Drug treatments quinolones resistance urinary tract infection Urinary Tract Infections - epidemiology Urinary Tract Infections - microbiology |
| title | Quinolone resistance among Escherichia coli strains from community‐acquired urinary tract infections in Greece |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A42%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quinolone%20resistance%20among%20Escherichia%20coli%20strains%20from%20community%E2%80%90acquired%20urinary%20tract%20infections%20in%20Greece&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Chaniotaki,%20S.&rft.aucorp=WHONET%20Study%20Group&rft.date=2004-01&rft.volume=10&rft.issue=1&rft.spage=75&rft.epage=78&rft.pages=75-78&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1111/j.1469-0691.2004.00807.x&rft_dat=%3Cproquest_cross%3E19263852%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19263852&rft_id=info:pmid/14706091&rfr_iscdi=true |